安旭生物(688075) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 453.58 million, a decrease of 16.11% compared to RMB 540.70 million in the previous year[4] - Net profit attributable to shareholders was RMB 73.38 million, down 61.84% from RMB 192.30 million year-on-year[4] - The basic earnings per share decreased to RMB 0.58, a decline of 61.59% from RMB 1.51 in the previous year[4] - The return on equity decreased to 1.41%, down 2.31 percentage points from 3.72% in the previous year[4] - The net profit excluding non-recurring gains and losses was RMB 15.37 million, a decrease of 59.44% from RMB 37.90 million year-on-year[4] Assets and Investments - Total assets at the end of the reporting period were RMB 5,612.12 million, a decrease of 2.72% from RMB 5,769.31 million at the beginning of the period[4] - The company has increased its strategic investment in new technology platforms and is advancing product registration and certification domestically and internationally[6] Market and Operational Challenges - The decline in net profit was primarily due to increased tariffs imposed by the U.S. government, leading to reduced orders in certain markets and increased operating costs[7] - The company is expanding its overseas branch layout, which has resulted in increased sales expenses but is expected to open up space for future growth[6] - The company emphasizes the importance of operational upgrades centered on lean management to enhance efficiency and cost control[6]